SCHEMBL4138092

SCHEMBL4138092

CSc1ncc2cc(-c3ccccc3C)c(=O)[nH]c2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIK2 Q9H0K1 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
AURKA O14965 1/20 0.40
KDR P35968 1/20 0.40
AURKB Q96GD4 1/20 0.40
NPC1 O15118 1/20 0.39
HSP90AA1 P07900 1/20 0.38
RXFP1 Q9HBX9 3/20 0.38
LMNA P02545 1/20 0.38
HPGD P15428 1/20 0.38
MAPT P10636 1/20 0.38
GRIN1 Q05586 4/20 0.36
GRIN2B Q13224 4/20 0.36
LYN P07948 1/20 0.36
SRC P12931 1/20 0.36
BTK Q06187 1/20 0.36
POLB P06746 1/20 0.36
THRB P10828 1/20 0.36
AKT1 P31749 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4180912 0.86 MEN1 (0.40) SIK2MEN1KMT2ANPC1RXFP1
SCHEMBL29536534 0.86 SIK2 (0.47) SIK2MEN1KMT2AAURKAKDR
SCHEMBL4414517 0.86 MEN1 (0.40) SIK2MEN1KMT2ARXFP1MAPT
SCHEMBL14370847 0.86 SIK2 (0.47) SIK2MEN1KMT2AAURKAKDR
SCHEMBL19817053 0.85 MEN1 (0.42) SIK2MEN1KMT2AMAPT
SCHEMBL20564939 0.84 MEN1 (0.51) SIK2MEN1KMT2ARXFP1MAPT
SCHEMBL16414768 0.81 SIK2 (0.61) SIK2MEN1KMT2ARXFP1MAPT
SCHEMBL5262113 0.81 MEN1 (0.39) MEN1KMT2ANPC1RXFP1LMNA
SCHEMBL5659394 0.79 FGFR1 (0.45) SIK2MEN1KMT2AKDRLYN
SCHEMBL29536840 0.79 FGFR1 (0.45) SIK2MEN1KMT2AKDRLYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090221600-A1 PYRIDO-PYRIDIMIDINE DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-09-03 US disclosed
US-20090036472-A1 AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-02-05 US disclosed
WO-2008078249-A1 ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2008-07-03 WO disclosed
EP-1846403-A1 AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS Ranbaxy Laboratories Limited (IN) 2007-10-24 EP disclosed
WO-2006082492-A1 AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2006-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221600-A1 PYRIDO-PYRIDIMIDINE DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS PNPO, TPMT, NOD1 SIK2 3095/4885MEN1 3210/4885KMT2A 4273/4885
US-20090036472-A1 AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS IL1B, TPMT, IL1R1 SIK2 4195/4885MEN1 3606/4885KMT2A 3825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.